ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 23

Differential Effects of Bone Morphogenetic Protein 2 and 9 On Chondroprotective Transforming Growth Factor β Signaling

Arjan P. van Caam1, Esmeralda N. Blaney Davidson1, Elly L. Vitters2, Laurie de Kroon1, Ellen W. van Geffen3, Peter ten Dijke4, Wim B. van den Berg2 and Peter M. van der Kraan2, 1Rheumatology Research & Advanced Therapeutics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 2Rheumatology Research and Advanced Therapeutics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 3Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands, 4Department of Molecular Cell Biology, Leiden University Medical Center, Leiden, Netherlands

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: cell biology, chondrocytes, OA, signal transduction and transforming growth factor

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Biology and Pathology of Bone and Joint

Session Type: Abstract Submissions (ACR)

Background/Purpose: Osteoarthritis (OA) is a multifactorial disease characterized by loss of articular cartilage. TGFβ is considered as a protective factor against cartilage loss in young cartilage by inducing Smad2/3 phosphorylation via the TGFβ receptor ALK5. Smad2/3 phosphorylation  (Smad2/3P) lowers MMP13 expression, and prevents deleterious terminal differentiation of chondrocytes. In contrast to Smad2/3P, Smad1/5 phosphorylation (Smad1/5P), induced by BMPs but also by TGFβ, is linked to terminal differentiation and MMP13 production. Type I receptors that phosphorylate Smad1/5/8 include ALK1 and ALK3. BMP-9 signals via ALK1 and BMP-2 via ALK3,  and both ligands induce enhanced glycosaminoglycan synthesis in young cartilage. BMP2 is induced in damaged cartilage while BMP9 is constitutively present in high concentrations in body fluids. If and how these factors modulate chondroprotective TGFβ signaling is still unclear. Therefore, we analyzed BMP-2 and BMP-9 induced Smad signaling and gene expression in chondrocytes, and studied their interaction with TGFβ.

Methods: Primary bovine chondrocytes, isolated from the metacarpophalangeal joint of 2 year old animals, or the human G6 chondrocyte cell line were cultured to near confluency and incubated with TGFβ1, BMP-2, BMP-9 or a combination thereof. Smad phosphorylation kinetics were analyzed by specific Smad2P and Smad1/5P staining of Western blots. Expression patterns of  Smad specific response genes: PAI-1 (Smad3 signaling), and ID-1, (Smad1/5 signaling) were analyzed from 0-48h by quantitative real time PCR (qPCR). Biological activity was tested with a CAGA12-luc transcriptional reporter construct that produces luciferase in response to Smad3 signaling. Adenovirally transduced cells (MOI = 5) were serum starved for 8h, stimulated with growth factors for 20h, and luciferase activity was measured.

Results: In primary chondrocytes, both BMP-2 and BMP-9 potently induced Smad1/5 phosphorylation, which peeked after 1 h and lasted up to 3 h. BMP-9 was more potent than BMP2. Remarkably BMP-9 (5 ng/ml or more) was also capable of inducing Smad2 phosphorylation, whereas BMP-2 (50 ng/ml) was not. BMP-9-induced Smad2 phosphorylation lasted from 1 up to 3 hours. Moreover, in contrast to BMP-2, BMP-9 was also able to rapidly (from 2 up to 24h) induce PAI-1 transcription. Both growth factors potently induced ID1 expression. Gene transcription was reflected in biological activity, as BMP-9 induced luciferase production in the CAGA12-luc assay. Interestingly, co-stimulation of TGFβ with these BMPs revealed an even more remarkable difference between both factors. BMP-2 was able to dose dependently inhibit Smad2 phosphorylation. On the contrary, BMP-9 synergized with TGFβ on Smad2/3 phosphorylation, resulting in a 50% increase in luciferase production after co-stimulation compared to TGFβ alone (p<0.01).

Conclusion: Both BMPs show a distinct difference in Smad phosphorylation and interaction with TGFβ. Although both BMPs promote matrix synthesis (Glycosaminoglycans production), long term effects of both factors on cartilage will most likely differ due to their different effects on chondroprotective Smad2/3 signaling.


Disclosure:

A. P. van Caam,
None;

E. N. Blaney Davidson,
None;

E. L. Vitters,
None;

L. de Kroon,
None;

E. W. van Geffen,
None;

P. ten Dijke,
None;

W. B. van den Berg,
None;

P. M. van der Kraan,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/differential-effects-of-bone-morphogenetic-protein-2-and-9-on-chondroprotective-transforming-growth-factor-%ce%b2-signaling/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology